These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11445875)

  • 21. Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-alpha double-deficient mice.
    Eugster HP; Muller M; Karrer U; Car BD; Schnyder B; Eng VM; Woerly G; Le Hir M; di Padova F; Aguet M; Zinkernagel R; Bluethmann H; Ryffel B
    Int Immunol; 1996 Jan; 8(1):23-36. PubMed ID: 8671586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor.
    Hoon DS; Banez M; Okun E; Morton DL; Irie RF
    Cancer Res; 1991 Apr; 51(8):2002-8. PubMed ID: 1901239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice.
    Li P; Schwarz EM; O'Keefe RJ; Ma L; Looney RJ; Ritchlin CT; Boyce BF; Xing L
    Arthritis Rheum; 2004 Jan; 50(1):265-76. PubMed ID: 14730625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spontaneous cytotoxicity (SCMC) of normal human lymphocytes against a human melanoma cell line: a phenomenon due to a lymphotoxin-like mediator.
    Peter HH; Eife RF; Kalden JR
    J Immunol; 1976 Feb; 116(2):342-8. PubMed ID: 1082453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin.
    Bialas T; Kolitz J; Levi E; Polivka A; Oez S; Miller G; Welte K
    Cancer Res; 1988 Feb; 48(4):891-8. PubMed ID: 3257413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.
    Wu X; Giobbie-Hurder A; Liao X; Lawrence D; McDermott D; Zhou J; Rodig S; Hodi FS
    Cancer Immunol Res; 2016 Oct; 4(10):858-868. PubMed ID: 27549123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in the biological activity of TNF alpha and TNF beta correlate with their different abilities for binding to the target cells.
    Kircheis R; Milleck J; Korobko VG; Shingarova LN; Schmidt HE
    Eur Cytokine Netw; 1992; 3(4):381-90. PubMed ID: 1330049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of recombinant murine tumor necrosis factor-alpha on immune function.
    Gordon C; Wofsy D
    J Immunol; 1990 Mar; 144(5):1753-8. PubMed ID: 2307839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE; Tsiatas ML; Gritzapis AD; Papamichail M
    Eur J Immunol; 2000 Jul; 30(7):1957-66. PubMed ID: 10940885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correction or transfer of immunodeficiency due to TNF-LT alpha deletion by bone marrow transplantation.
    Müller M; Eugster HP; Le Hir M; Shakhov A; Di Padova F; Maurer C; Quesniaux VF; Ryffel B
    Mol Med; 1996 Mar; 2(2):247-55. PubMed ID: 8726467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphoid hyperplasia, CD45RBhigh to CD45RBlow T-cell imbalance, and suppression of Type I diabetes mellitus result from TNF blockade in NOD-->NOD-scid adoptive T cell transfer.
    Brown GR; Silva MD; Thompson PA; Beutler B
    Diabetologia; 1998 Dec; 41(12):1502-10. PubMed ID: 9867218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endotoxin induces parathyroid hormone-related protein gene expression in splenic stromal and smooth muscle cells, not in splenic lymphocytes.
    Funk JL; Lausier J; Moser AH; Shigenaga JK; Huling S; Nissenson RA; Strewler GJ; Grunfeld C; Feingold KR
    Endocrinology; 1995 Aug; 136(8):3412-21. PubMed ID: 7628377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukocyte subpopulations elicited by a nontumorigenic variant of B16 melanoma: their role in direct rejection of the melanoma and in prevention of tumorigenesis in Winn assays.
    Calvelli TA; Freedman VH; Silverstein SC; Silagi S
    J Exp Med; 1982 Dec; 156(6):1723-38. PubMed ID: 6983560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complementation of lymphotoxin alpha knockout mice with tumor necrosis factor-expressing transgenes rectifies defective splenic structure and function.
    Alexopoulou L; Pasparakis M; Kollias G
    J Exp Med; 1998 Aug; 188(4):745-54. PubMed ID: 9705956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
    Yamamoto N; Zou JP; Li XF; Takenaka H; Noda S; Fujii T; Ono S; Kobayashi Y; Mukaida N; Matsushima K
    J Immunol; 1995 Mar; 154(5):2281-90. PubMed ID: 7868900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in the bioactivity of recombinant human TNF, LT, and T-cell-derived LT-3 on transformed cells in vitro and the Meth A tumor growing in BALB/c mice.
    Granger GA; Masunaka I; Averbook B; Kobayashi M; Fitzgerald M; Yamamoto R
    J Biol Response Mod; 1988 Oct; 7(5):488-97. PubMed ID: 3263472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TNF-alpha released by comigrating monocytes promotes transendothelial migration of activated lymphocytes.
    Green DM; Trial J; Birdsall HH
    J Immunol; 1998 Sep; 161(5):2481-9. PubMed ID: 9725247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles.
    Mortarini R; Scarito A; Nonaka D; Zanon M; Bersani I; Montaldi E; Pennacchioli E; Patuzzo R; Santinami M; Anichini A
    Cancer Res; 2005 Apr; 65(8):3428-36. PubMed ID: 15833878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells.
    Thomas WD; Hersey P
    J Immunol; 1998 Sep; 161(5):2195-200. PubMed ID: 9725211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.